Research graph
References from Monitoring ovarian reserve dynamics via a high-sensitivity anti-Müllerian hormone assay in premenopausal breast cancer patients undergoing chemotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Ovarian stiffness increases with age in the mammalian ovary and depends on collagen and hyaluronan matrices
10.1111/acel.13259 · 2020 · External reference
ESHRE guideline: female fertility preservation
10.1093/hropen/hoaa052 · 2020 · External reference
Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review
10.1093/humupd/dmac004 · 2022 · External reference
Pretreatment serum anti-Müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer
10.1210/jc.2010-2582 · 2011 · External reference
The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer
10.1016/j.ejca.2017.10.001 · 2017 · External reference
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin’s lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial
10.1016/s1470-2045(18)30500-x · 2018 · External reference
Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer
10.1016/j.ejca.2013.07.014 · 2013 · External reference
Reproductive age-associated fibrosis in the stroma of the mammalian ovary
10.1530/rep-16-0129 · 2016 · External reference
Single molecule enzyme-linked immunosorbent assays: theoretical considerations
10.1016/j.jim.2012.02.011 · 2012 · External reference
The quality of human eggs and its pre-IVF incubation
10.1002/rmb2.12652 · 2025 · External reference
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement
10.1016/s1470-2045(23)00390-x · 2023 · External reference
AMH as the primary marker for fertility
10.1530/eje-19-0373 · 2019 · External reference
Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer
10.1016/j.ejca.2017.03.035 · 2017 · External reference
Re-implantation of cryopreserved ovarian cortex resulting in restoration of ovarian function, natural conception and successful pregnancy after haematopoietic stem cell transplantation for Wilms tumour
10.1007/s10815-016-0805-2 · 2016 · External reference
Fertility and ageing
10.1093/humupd/dmi006 · 2005 · External reference
Biomechanical forces and signals operating in the ovary during folliculogenesis and their dysregulation: implications for fertility
10.1093/humupd/dmac031 · 2023 · External reference
Anti-Müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy
10.1016/j.ejca.2016.12.008 · 2017 · External reference
Breast Cancer Statistics, 2022
2022 · External reference
Correlation of ovarian reserve tests with histologically determined primordial follicle number
10.1016/j.fertnstert.2010.04.006 · 2011 · External reference
Ovarian function, fertility and reproductive lifespan in cancer patients
10.1080/17446651.2018.1455498 · 2018 · External reference
V. ery low levels of serum anti-Müllerian hormone as a possible marker for follicle growth in patients with primary ovarian insufficiency under hormone replacement therapy
10.1007/s43032-020-00278-4 · 2021 · External reference
A validated model of serum anti-Müllerian hormone from conception to menopause
10.1371/journal.pone.0022024 · 2011 · External reference
Post-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recovery
10.1530/ec-18-0180 · 2018 · External reference
Development of a digital anti-Mullerian hormone immunoassay: ultrasensitive, accurate and practical strategy for reduced ovarian reserve monitoring and assessment
10.1016/j.talanta.2022.123970 · 2023 · External reference
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data
10.1200/jco.2018.78.0858 · 2018 · External reference
Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines(dagger)
10.1016/j.annonc.2020.09.006 · 2020 · External reference
O. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients
10.1200/jco.2006.06.5888 · 2006 · External reference
GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial
10.1093/annonc/mdx184 · 2017 · External reference
Fertility preservation for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
10.1200/jco.2013.49.2678 · 2013 · External reference
Evolution of serum anti-Mullerian hormone (AMH) level in young women treated with chemotherapy for breast cancer according to basal AMH level
10.1016/j.ejogrb.2020.09.016 · 2020 · External reference
Anti-Mullerian hormone for the diagnosis and prediction of menopause: a systematic review
10.1093/humupd/dmac045 · 2023 · External reference
Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update
10.1200/jco.2018.78.1914 · 2018 · External reference
Spatiotemporal changes in mechanical matrisome components of the human ovary from prepuberty to menopause
10.1093/humrep/deaa100 · 2020 · External reference
Premature ovarian insufficiency: an International Menopause Society White Paper
10.1080/13697137.2020.1804547 · 2020 · External reference
Progress in adjuvant systemic therapy for breast cancer
10.1038/s41571-018-0089-9 · 2019 · External reference
Cancer treatment-related infertility: a critical review of the evidence
10.1093/jncics/pkz008 · 2019 · External reference
Cancer treatment-related ovarian dysfunction in women of childbearing potential: management and fertility preservation options
10.1200/jco.22.01885 · 2023 · External reference
Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations
10.1038/nbt.1641 · 2010 · External reference
Interactions between serum FSH, inhibin B and antral follicle count in the decline of serum AMH during the menstrual cycle in late reproductive age
10.1002/edm2.172 · 2021 · External reference
AntiMullerian hormone as a serum biomarker for risk of chemotherapy-induced amenorrhea
10.1093/jnci/djaa160 · 2021 · External reference
Female fertility loss and preservation: threats and opportunities
10.1093/annonc/mds514 · 2013 · External reference
Modeling variation in the reproductive lifespan of female adolescent and young adult cancer survivors using AMH
10.1210/clinem/dgaa172 · 2020 · External reference
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2021 · External reference
Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China
10.1093/humrep/deaa349 · 2021 · External reference
ESHRE Guideline: management of women with premature ovarian insufficiency
10.1093/humrep/dew027 · 2016 · External reference
Safety and efficacy of allogenic human amniotic epithelial cells transplantation via ovarian artery in patients with premature ovarian failure: a single-arm, phase 1 clinical trial
10.1016/j.eclinm.2024.102744 · 2024 · External reference
Age and fecundability in a North American preconception cohort study
10.1016/j.ajog.2017.09.002 · 2017 · External reference
Effects of gonadotropin-releasing hormone analogs on ovarian function against chemotherapy-induced gonadotoxic effects in premenopausal women with breast cancer in China: a randomized clinical trial
10.1001/jamaoncol.2021.6214 · 2022 · External reference
